Advertisement

Topics

NantKwest Announces Durable Complete Responses In Ph1 Trial Of Ank Cell Therapy In Patients With Relapsed Hematological Malignancies

20:00 EDT 31 Jul 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: NantKwest Announces Durable Complete Responses In Ph1 Trial Of Ank Cell Therapy In Patients With Relapsed Hematological Malignancies

NEXT ARTICLE

More From BioPortfolio on "NantKwest Announces Durable Complete Responses In Ph1 Trial Of Ank Cell Therapy In Patients With Relapsed Hematological Malignancies"

Quick Search
Advertisement